Is Virax Biolabs Group Limited (VRAX) Overvalued or Undervalued?Intrinsic Value Overview
Virax Biolabs Group Limited (VRAX)
Virax Biolabs Group Limited (VRAX) intrinsic value summary: current price $0.21, fair value N/A, N/A implied move via DCF and relative valuation.
Method Breakdown
Base blend: 60% DCF + 40% RelativeCompany Quality
Weak fundamentals — significant concerns
Wall St Estimates
Shareholder Returns
Total Return vs S&P 500
Fundamental Analysis
Profitability & Financial HealthProfitability
Returns & MarginsSolvency
Financial HealthGrowth & Margins
Quarterly Trends · 5-Year Window · Hover for detailPiotroski F-Score
Fundamental QualityMonte Carlo Distribution & Risk
10,000 SimulationsAnnual Returns vs SPY
Total Return (Price + Dividends)| Year | Stock Return | SPY Return | Alpha |
|---|---|---|---|
| 2026YTD | -40.7% | +0.4% | -41.1% |
| 2025 | -84.3% | +16.6% | -101.0% |
| 2024Best | +64.2% | +24.0% | +40.2% |
| 2023 | -81.8% | +24.8% | -106.6% |
| 2022Worst | -96.0% | -19.9% | -76.0% |
Frequently Asked Questions
ValuationIs VRAX a good stock to buy right now?
Based on our multi-model analysis of Virax Biolabs Group Limited (VRAX) at $0.21: Fundamental quality score: 30/100 (below average). This is a quantitative summary combining DCF intrinsic value, peer-based relative valuation, quality scoring, and analyst consensus — not a buy/sell recommendation. Always consult a qualified financial advisor before investing.
ValuationWhat is Virax Biolabs Group Limited's fair value?
Fair value data is not yet available for VRAX.
QualityIs VRAX financially healthy?
Virax Biolabs Group Limited's financial health as measured by our composite scoring: Overall quality score: 30/100. Piotroski F-Score: 1/9 (weak fundamentals). Altman Z-Score: -6.8 (distress zone — elevated risk). Return on invested capital: -273.2%. Cash conversion (OCF/NI): 0.75x (earnings exceed cash generation). The quality score blends profitability (ROIC, ROE, margins), solvency (leverage, coverage, Z-Score), and growth trajectory into a single 0–100 framework updated end-of-day.
PerformanceHow has VRAX performed compared to the S&P 500?
Virax Biolabs Group Limited's performance profile: 1-year total return: -84.6%. 1-year alpha vs S&P 500: -101.3% (underperforming the benchmark). 5-year CAGR: -74.2%. Maximum drawdown (1Y): -88.0%. Relative Strength rating: 5/99 (weak momentum). Beta: 1.24 (more volatile than the market). Total returns include reinvested dividends. Alpha is calculated against the S&P 500 Total Return Index over matching periods.
IncomeDoes VRAX pay dividends?
Virax Biolabs Group Limited does not currently pay a dividend or conduct significant share buybacks. The company is retaining capital for reinvestment.
EstimatesWhat do Wall Street analysts say about VRAX?
No analyst coverage data available for VRAX.
RiskWhat are the key risks of investing in VRAX?
Key risks identified for Virax Biolabs Group Limited: Drawdown risk: The stock experienced a -88.0% max drawdown in the past year. Solvency risk: Altman Z-Score (-6.8) is in the distress zone, indicating elevated bankruptcy risk. Note: This model does not capture regulatory changes, management decisions, competitive disruption, or geopolitical events. Macro and qualitative risks remain material and should be assessed independently.
LegalDoes this dashboard provide investment advice?
No. This overview dashboard aggregates data from our DCF intrinsic value model, relative peer multiples model, proprietary estimates engine, and third-party analyst consensus feeds. It is strictly for educational and informational purposes. The operator of this platform is not a registered investment advisor (RIA), broker-dealer, or financial planner. All model outputs, fair value estimates, quality scores, and signals are automated quantitative computations and should not be construed as investment recommendations. Consult a qualified, licensed financial advisor before making any investment decisions. Past model performance does not guarantee future results.